期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 53, 期 -, 页码 13-24出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2020.05.009
关键词
IL-6; SARS-CoV-2; Cytokine release syndrome; Anti-cytokine therapeutics
资金
- Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1660]
- Russian Science Foundation [19-75-30032]
- Russian Science Foundation [19-75-30032] Funding Source: Russian Science Foundation
COVID-19 mortality is strongly associated with the development of severe pneumonia and acute respiratory distress syndrome with the worst outcome resulting in cytokine release syndrome and multiorgan failure. It is becoming critically important to identify at the early stage of the infection those patients who are prone to develop the most adverse effects. Elevated systemic interleukin-6 levels in patients with COVID-19 are considered as a relevant parameter in predicting most severe course of disease and the need for intensive care. This review discusses the mechanisms by which IL-6 may possibly contribute to disease exacerbation and the potential of therapeutic approaches based on anti-IL-6 biologics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据